EGFR and non-small cell lung carcinoma: Regarding the challenges of overcoming resistance, promising results are represented by the combination between ALK and epidermal growth factor receptor (EGFR) TKI, metformin, MYC (avian myelocytomatosis viral oncogene homolog) – inhibitors, human EGFR (HER) family, mammalian target of rapamycin (mTOR) pathway, anti-angiogenesis factors, etc. Nevertheless, the most awaited results are for the combination between ALK TKI and immunotherapy, which represents the most innovative therapeutic option for NSCLC patients [11-14].